• Metastatic Cervical Cancer Treatment Granted FDA Fast Track Designation americanpharmaceuticalreview
    August 19, 2020
    Akeso announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for AK104, a novel anti-PD-1/CTLA-4 bi-specific antibody, as monotherapy for the treatment of patients with recurrent or metastatic squamous cervical cancer ...
PharmaSources Customer Service